Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so challenging. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At our core, we’re a biopharmaceutical company passionately committed to applying our leadership in the field of cellular metabolism to transform the lives of patients. We’re a science-driven, patient-focused organization developing transformative therapies across three major focus areas: hematologic malignancies, solid tumors and rare genetic diseases. Patients are counting on us, and we’re driven by a sense of urgency to help. We challenge ourselves to think big and welcome different perspectives and backgrounds. And we deliver. We have two approved oncology precision medicines and multiple first-in-class investigational therapies in development. So far. Our research engine continues to yield new insights and potential therapeutic approaches, growing our differentiated portfolio of preclinical, clinical and commercial programs. Through it all, we are propelled by our connections with one another and our shared goal of doing something extraordinary on behalf of those in need. Together, we can achieve the Other Side of Possible.
The core of Agios remains our research engine, from a robust discovery toolkit to a focus on the deep biological interrogation of prospective targets and mechanisms of action. Translational thinking is embedded across programs early in research, to ensure a rapid and successful transition to the clinic. Once in the clinic, we embrace trial designs that allow for rapid clinical proof of concept, guiding the subsequent development path. We are committed to leveraging our established and growing commercial presence to both deliver medicines to patients worldwide and maximize value for Agios and its partners. Across all functions and stages of development, Agios embraces its “Other Side of Possible” (OSOP) culture to accomplish the extraordinary while prioritizing the patients whom we seek to serve.